Dr. Evan Yu

Dr. Yu cares for patients with prostate, bladder and testicular cancers. He has research interests in novel PET imaging technologies in prostate cancer. Additionally, he is interested in manipulating the prostate cancer microenvironment to convert an immune exclusive microenvironment to an inflamed phenotype that will promote the utility of immunotherapy. He also does work in developing antibody drug conjugates for patients with bladder cancer.

He has research projects that span the spectrum of drug discovery and early phase testing all the way to leading large, international randomized Phase 3 clinical trials with promise to lead to new U.S. Food and Drug Administration (FDA) approvals. For example, he is working with new immune checkpoint inhibitors that target VISTA, agents that alter the immunosuppressive microenvironment by decreasing adenosine accumulation, novel adrenal androgen annihilators and androgen receptor degraders, and HER2 targeting in bladder cancer using antibody drug conjugates.

Dr. Yu is section head of Medical Oncology in the Clinical Research Division at Fred Hutch. He also serves as the medical director for Clinical Research for the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium. He is a principal investigator, or PI, for the National Cancer Trials Network Lead Academic Performance Site (LAPS) Grant, SWOG Cancer Research Network and Eastern Cooperative Oncology Group/American College of Radiology Imaging Network. Dr. Yu is also the core director for the Pacific Northwest Prostate Cancer SPORE and co-PI of the DoD Prostate Cancer Clinical Trials Consortium for Fred Hutch. Previously, he served as director of the Hematology/Oncology Fellowship Program for a decade at Fred Hutch.

Dr. Yu has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is currently the co-chair for the National Cancer Institute Prostate Cancer Task Force. He has held various leadership or committee roles within the American Society of Clinical Oncology, the American Association for Cancer Research and serves as a senior editor for Clinical Cancer Research and Uro-Today.